The Placebo Nobody Tested, and What It Reveals About Tirzepatide

Key Takeaway

Until now, tirzepatide’s cardiovascular benefit could only be measured against another active drug. By mathematically anchoring SURPASS-CVOT to REWIND, this analysis estimates a 28% reduction in major cardiovascular events and a 39% reduction in all-cause death compared with no incretin therapy. That is a compelling signal, but it is a modeled one, not randomized proof.

The Trial That Couldn’t Use a Sugar Pill

Picture a 63-year-old man in clinic. He is 2 years past a stent in his left anterior descending artery, his HbA1c is stuck at 8.1%, and his body mass index is 33. He asks the question every patient eventually asks: how much will this injection actually help me? For tirzepatide, the honest answer has been oddly elusive. SURPASS-CVOT compared it not with placebo but with dulaglutide, a drug already proven to reduce cardiovascular events^[2]. Tirzepatide proved noninferior, not superior^[3]. That tells us it matches a good drug. It does not tell us how…